Abstract:Background: Nuclear factor E2-related factor 2 (Nrf2) is a regulator of the cellular adaptive response to oxidative stress, but its effects on microvascular function are poorly characterized. Our previous studies in human glomerular endothelial cells found that tert-butylhydroquinone (tBHQ; a Nrf2 activator) reduced ROS, asymmetric dimethylarginine (ADMA, an endogenous NOS inhibitor) and increased eNOS. We hypothesized that tBHQ would prevent microvascular endothelial dysfunction via activation of Nrf2 / antioxidant responses in angiotensin II (ANG II) induced hypertension. Methods: Mesenteric resistance arterioles (MRAs) were isolated from mice infused for 14 days with ANG II (400 ng/kg/min) or vehicle and given oral tBHQ (0.1% of water) or vehicle (n=6 mice/group). Acetylcholine-induced endothelium dependent relaxation (EDR), endothelial derived relaxation factor (EDRF) and contracting factor (EDCF) of MRAs were assessed by myograph. Vascular nitric oxide (NO), and ROS were assessed by RatioMaster. ROS biomarkers (urinary excretion of malondialdehyde [MDA]) and 8-isoprotane [8-Iso]), ADMA and protein expressions of MRAs were measured. Results: tBHQ prevented the effects (all P<0.05) of ANG II infusion-induced the increases of urinary MDA (50±3 vs 83±11 nmol/mg creatine) and 8-Iso (1.4±0.1 vs 3.8±0.3 vs ng/mg creatinine) and decreases of EDR (75 ± 3 vs 53±5%), EDRF (23± 2 vs 17± 3%) and NO (0.3 ± 0.02 vs 0.2 ± 0.03 units), and enhanced EDCF (7 ± 1 vs 13 ± 2%) and associated ROS production (0.11 ± 0.03 vs 0.3 ± 0.08 units) and microvascular ADMA (18 ± 1 vs 13 ± 1 nmol/mg protein). ANG II increased the MRAs protein expressions (of β-actin, all P<0.05) for NOX1 (0.60 ± 0.03 vs 0.38± 0.04) and NOX2 (0.80 ± 0.04 vs 0.36± 0.05) and reduced phosphorylated eNOS (0.26 ±0.07 vs 0.53±0.09), whereas tBHQ increased Nrf2 expression (0.44 ±0.03 vs 0.73±0.04) and prevented these changes with ANG II infusion. Conclusions: tBHQ upregulates Nrf2 and thereby engages the antioxidant responses to protect microvessels of ANG II-infused mice from the adverse effectors of ROS, NO deficiency and ADMA. This is a novel potential therapeutic target that activates Nrf2/antioxidant response element to protect against vascular oxidative stress, endothelial dysfunction and CVD.

Central Administration of Tert-Butylhydroquinone Attenuates Hypertension Via Regulating Nrf2 Signaling in the Hypothalamic Paraventricular Nucleus of Hypertensive Rats

Tert-butylhydroquinone attenuates oxidative stress and inflammation in hypothalamic paraventricular nucleus in high salt-induced hypertension.

Chronic Reduction in Paraventricular Nucleus (PVN) AT1R Expression by AAV‐mediated Transfer of a Small Hairpin RNA (shrna) Produces a Decrease in Blood Pressure in Spontaneously Hypertensive Rats

Abstract 394: Chronic Knockdown of the NTS AT1R Increases Circulating Inflammatory-Endothelial Progenitor Cells Ratio and Exacerbates Hypertension in the SHR

Nucleus of the Solitary Tract (pro)renin Receptor-Mediated Antihypertensive Effect Involves Nuclear Factor-Κb-cytokine Signaling in the Spontaneously Hypertensive Rat.

The effect of chronic tBHQ treatment on high salt-induced hypertension is reported • Chronic tBHQ supplementation attenuates hypertension and sympathoexcitation • Chronic tBHQ supplementation attenuates PVN oxidative stress and inflammation

Chronic Infusion of Epigallocatechin-3- O -Gallate into the Hypothalamic Paraventricular Nucleus Attenuates Hypertension and Sympathoexcitation by Restoring Neurotransmitters and Cytokines

Resveratrol in the Hypothalamic Paraventricular Nucleus Attenuates Hypertension by Regulation of ROS and Neurotransmitters

Inhibition of NF-κB activity in the hypothalamic paraventricular nucleus attenuates hypertension and cardiac hypertrophy by modulating cytokines and attenuating oxidative stress.

Nrf1 Knock-Down in the Hypothalamic Paraventricular Nucleus Alleviates Hypertension Through Intervention of Superoxide Production-Removal Balance and Mitochondrial Function

Inhibition of Reactive Oxygen Species in Hypothalamic Paraventricular Nucleus Attenuates the Renin-Angiotensin System and Proinflammatory Cytokines in Hypertension

Chronic infusion of berberine into the hypothalamic paraventricular nucleus attenuates hypertension and sympathoexcitation via the ROS/Erk1/2/iNOS pathway

Central Administration of AICAR Attenuates Hypertension Via AMPK/Nrf2 Pathway in the Hypothalamic Paraventricular Nucleus of Hypertensive Rats.

NRF2 Prevents Hypertension, Increased ADMA, Microvascular Oxidative Stress, and Dysfunction in Mice with Two Weeks of ANG II Infusion

Effects of Nrf1 in Hypothalamic Paraventricular Nucleus on Regulating the Blood Pressure During Hypertension

Luteolin Attenuates Hypertension via Inhibiting NF-κB-Mediated Inflammation and PI3K/Akt Signaling Pathway in the Hypothalamic Paraventricular Nucleus

Inhibition of CB1R in the Hypothalamic Paraventricular Nucleus Ameliorates Hypertension Through Wnt/β-Catenin/RAS Pathway

Abstract 109: Protective Effects of Nuclear Factor E2-related Factor 2 Activation on Angiotensin II Induced Microvascular Endothelial Dysfunction

Exercise Training Attenuates Hypertension Via Suppressing ROS/MAPK/NF-κB/AT-1R Pathway in the Hypothalamic Paraventricular Nucleus

Inhibition of TNF-α in Hypothalamic Paraventricular Nucleus Attenuates Hypertension and Cardiac Hypertrophy by Inhibiting Neurohormonal Excitation in Spontaneously Hypertensive Rats.

Taurocholic acid ameliorates hypertension through activation of TGR5 in hypothalamic paraventricular nucleus